Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ixazomib→

Ixazomib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1072833-77-2
Molecular formula
C14H19BCl2N2O4
Molecular weight
361 g/mol
Drug class
Proteasome Inhibitor
Mechanism of action
Proteasome Inhibitors
Indications / reported uses
  • Multiple Myeloma
  • patients with multiple myeloma who have received at least one prior therapy

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ixazomib Environmental Risk Assessment (ERA) (the Ixazomib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.